DALLAS, Feb. 6, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY. Details for the presentation are as follows:
Ms. Bhattacharya will provide an update on Nanoscope’s clinical and corporate activities on Monday, February 10, at 4:30 PM Eastern Time in the Plymouth Room. Nanoscope leadership will be available for meetings during the conference. Attendees interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering.
“With our upcoming BLA submission for MCO-010, Nanoscope is on the cusp of providing meaningful sight restoration for patients suffering from retinitis pigmentosa,” said Ms. Bhattacharya. “I appreciate this opportunity to highlight for attendees the benefits and applications of MCO-010 therapy as well as discuss our other clinical programs in development for indications with significant unmet need. I’m looking forward to another productive event.”
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
SOURCE Nanoscope Therapeutics
